Daunorubicin

Daunorubicin

Clinical data
Pregnancy category	D (U.S.)
Routes of administration	Exclusively intravenous. Causes severe necrosis if administered intramuscularly or subcutaneously
ATC code	L01DB02 (WHO)
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	26.7 hours (metabolite)
Excretion	Biliary and urinary
Identifiers
IUPAC name (8S,10S)-8-acetyl-10-[(2S,4S,5S,6S)- 4-amino-5-hydroxy-6-methyl-oxan- 2-yl]oxy-6,8,11-trihydroxy-1-methoxy- 9,10-dihydro-7H-tetracene-5,12-dione
CAS Number	20830-81-3
PubChem CID	30323
DrugBank	APRD00521
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C27H29NO10
Molar mass	527.52 g/mol 563.99 g/mol (HCl salt)

WikiDoc Resources for Daunorubicin
Articles
Most recent articles on Daunorubicin Most cited articles on Daunorubicin Review articles on Daunorubicin Articles on Daunorubicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Daunorubicin Images of Daunorubicin Photos of Daunorubicin Podcasts & MP3s on Daunorubicin Videos on Daunorubicin
Evidence Based Medicine
Cochrane Collaboration on Daunorubicin Bandolier on Daunorubicin TRIP on Daunorubicin
Clinical Trials
Ongoing Trials on Daunorubicin at Clinical Trials.gov Trial results on Daunorubicin Clinical Trials on Daunorubicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Daunorubicin NICE Guidance on Daunorubicin NHS PRODIGY Guidance FDA on Daunorubicin CDC on Daunorubicin
Books
Books on Daunorubicin
News
Daunorubicin in the news Be alerted to news on Daunorubicin News trends on Daunorubicin
Commentary
Blogs on Daunorubicin
Definitions
Definitions of Daunorubicin
Patient Resources / Community
Patient resources on Daunorubicin Discussion groups on Daunorubicin Patient Handouts on Daunorubicin Directions to Hospitals Treating Daunorubicin Risk calculators and risk factors for Daunorubicin
Healthcare Provider Resources
Symptoms of Daunorubicin Causes & Risk Factors for Daunorubicin Diagnostic studies for Daunorubicin Treatment of Daunorubicin
Continuing Medical Education (CME)
CME Programs on Daunorubicin
International
Daunorubicin en Espanol Daunorubicin en Francais
Business
Daunorubicin in the Marketplace Patents on Daunorubicin
Experimental / Informatics
List of terms related to Daunorubicin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Daunorubicin or daunomycin (daunomycin cerubidine) is chemotherapy of the anthracycline family that is given as a treatment for some types of cancer. It is most commonly used to treat specific types of leukaemia (acute myeloid leukemia and acute lymphocytic leukemia). It was initially isolated from Streptomyces peucetius.

Uses

It slows or stops the growth of cancer cells in the body. Treatment is usually together with other chemotherapy drugs (such as cytarabine), and its administration depends on the type of tumor and the degree of response.

In addition to its major use in treating AML, daunorubicin is also used to treat neuroblastoma. Daunorubicin has been used with other chemotherapy agents to treat the blastic phase of chronic myelogenous leukemia.

Mode of action

On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunomycin effectively binds to every 3 base pairs and induces a local unwinding angle of 11^o, but negligible distortion of helical conformation.

Route of administration

Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

External links

• CancerBacup - Individual Drugs
• Mediline Plus - Drug Info

de:Daunorubicin ko:다우노루비신 Template:Jb1 Template:WH Template:WikiDoc Sources